India, Feb. 8 -- KeyMed Biosciences announced that the National Medical Products Administration of China has approved the supplemental New Drug Application of Stapokibart (anti-IL-4Ra monoclonal antibody, trade name: Kangyueda), for the treatment of seasonal allergic rhinitis.
Stapokibart is a humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4R- alpha), and is the first domestically manufactured IL-4R-Alpha antibody drug granted marketing approval by the NMPA. By targeting IL-4R-Alpha , Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation.
Stapokibart has demonstrated good safety and encouraging efficacy in mult...